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Mental Health Consumer and Caregiver Perceptions of Stigma in Australian Community 
Pharmacies 
 
Stigma associated with mental illness has been widely documented since the early 1950s 
(Rabkin, 1974) and presents a barrier to recovery by negatively affecting social status, self-
esteem, and social networks (Mental Health Council of Australia, 2011).  Stigma occurs in 
the form of public stigma or an internalized response to stigma (self-stigma).  Public stigma 
refers to the negative ways in which the general population react to people who have been 
identified as having a mental illness.  Internalized or self-stigma refers to negative self-beliefs 
that persons with mental illness hold and the associated impact on behaviour (Corrigan & 
Watson, 2002; Drapalski et al., 2013).  Recent Australian surveys indicate that stigma is 
commonly experienced (Reavley & Jorm, 2011).  For example, the National Mental Health 
Charity, SANE Australia, reported that 75% of 427 people with mental illness surveyed had 
experienced public stigma or discrimination in the previous 12 months (Thompson & Little, 
2011).  This finding is of concern given that this rate is no different to the 74% found in 2006 
(SANE Media Centre, 2011) and in light of the increased attention to addressing stigma 
world-wide.  
 
Stigmatising and discriminatory attitudes regarding mental illness exist in the general 
population, health professionals and health students in training.  Members of the public have 
been reported to view people with mental illness with fear, dislike, and express a desire to 
remain socially distant (Angermeyer & Matschinger, 2003; Martin, Pescosolido, & Tuch, 
2000).  Stigmatising views include the belief that mental illness is self-inflicted, that people 
with a mental illness are hard to communicate with, or likely to display violent behaviour 
(Crisp & Gelder, 2000; Jorm, Korten, Jacomb, Christensen, & Henderson, 1999; Kai & 
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Crosland, 2001; Kobau, Dilorio, Chapman, Delvecchio, & Members, 2010; Scheerder et al., 
2011).  Similar attitudes held by health professionals affect the provision of care to mental 
health consumers and caregivers (Jorm et al., 1999; Mental Health Council of Australia, 
2011; Phokeo, Sproule, & Raman-Wilms, 2004; Scheerder, De Coster, & Van Audenhove, 
2009).  Inclusion of information identifying a person as having mental illness can result in 
health professionals making a biased interpretation of behaviour (Farina & Felner, 1973).  
For example, a study which compared mental health professionals with the general public 
found health professionals rated descriptors such as ‘abnormal’ and ‘stupid’ as more 
characterising of people with mental illness than did the public (Lauber et al. 2006).  
Research shows that consumers commonly perceive and experience stigma from health 
professionals including psychiatrists, general practitioners (GPs), mental health nurses and 
psychologists (Thompson & Little, 2011; Wahl, 1999).  Negative beliefs and stigmatising 
attitudes also exist among students of pharmacy (Bell et al., 2010; Bell, Johns, & Chen, 2006; 
Volmer, Maesalu, & Bell, 2008), nursing (Keane, 1991), and medicine (for example, El magd 
& Al Zamil, 2013; Mas & Hatim, 2002; Mukherjee, Fialho, Wijetunge, Checinski, & 
Surgenor, 2002). 
 
Studies of mental health consumers show that they perceive themselves as stigmatised, 
encounter rejection and discrimination, and experience reduced life satisfaction (for a review, 
see Wahl, 1999).  Depending on the situation, consumers’ emotional reactions to stigma 
experiences might include anger, hurt, sadness, and discouragement (Corrigan & Watson, 
2002; Wahl, 1999, 2011).  Long-term consequences include lowered self-esteem and self-
confidence, avoidance of social contact or disclosure, and experiences that further contribute 
to anxiety and depression (Boyd Ritsher, 2003).  Coping strategies include advocacy and use 
of selective disclosure about mental illness (Wahl, 1999).  
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A widespread lack of accurate knowledge and negative attitudes contribute to the difficulties 
faced by this vulnerable population (Angermeyer & Dietrich, 2006; Corrigan & Watson, 
2002; Wahl, 1999; World Health Organization, 2001).  Given the prevalence and negative 
impact of stigma, efforts to reduce the experience of stigma are warranted.  Consumers have 
recommended public education about mental illness as an anti-stigma strategy, and in one 
survey, two out of three participants believed that mental health caregivers needed to be 
better informed (Wahl, 1999).  However, some findings suggest mixed results: informing 
people about mental illness might not necessarily affect attitudes or lead to reduced stigma 
(Angermeyer & Dietrich, 2006; Griffiths, Christensen, Jorm, Evans, & Groves, 2004; 
Schomerus et al., 2012).  
 
Almost half of all Australians (45.5%) are affected by mental illness in their lifetime (Slade, 
Johnston, Oakley Browne, Andrews, & Whiteford, 2009).  In Australia (as is the case 
internationally), mental health care is largely managed within the community (Wilson, 2000; 
World Health Organization and World Organization of Family Doctors, 2008).  Australian 
community pharmacy staff have regular contact with mental health consumers (defined here 
as persons with mental illness who obtain medicines and health care support from a 
community pharmacy) and caregivers through the ongoing supply of medicines and provision 
of primary health care services.  Therefore, community pharmacies are well placed to provide 
support and services to mental health consumers and caregivers.  In the Australian context, 
mental health reform is a national priority area (Commonwealth of Australia, 2009; Council 
of Australian Governments, 2012), and professional capability statements describe the high 
standards that are expected of community pharmacists in the provision of mental health care 
(Pharmaceutical Society of Australia, 2003, 2013).  
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A recent USA survey found that a sense of connectedness with pharmacy staff was the single 
strongest individual predictor of prescription medication adherence among Americans with 
chronic medical conditions, including mental illness (Langer Research Associates, 2013).  
However, the stigma associated with mental illness can act as a barrier to seeking or 
accessing the support available in community pharmacies (Mental Health Council of 
Australia, 2011).  For example, a survey of 79 consumers in Canada found that one in four 
persons (25%) with mental illness had experienced stigma within a community pharmacy 
(Black, Murphy, & Gardner, 2009).  
 
There appears to be greater research focus on public stigma towards people with mental 
illness (and the consequences for consumers), neglecting self-stigma.  The value of exploring 
consumer perspectives and how consumers engage with community pharmacy staff in 
shaping the delivery of mental health care is increasingly apparent (Salzburg Global Seminar, 
2011).  However, consumers’ perspectives regarding the stigma of mental illness in 
community pharmacy has not yet been sufficiently documented (Black et al., 2009).  In 
addition, there is a lack of evidence regarding the extent of stigma from community 
pharmacy staff providing medicines and services to mental health consumers and caregivers 
in Australia.  Exploring the stigma of mental illness can inform future community pharmacy 
initiatives on provision of patient centred health care.  
 
This article examined the perceptions and experiences of stigma within the Australian 
community pharmacy setting through the lens of persons with mental illness (consumers) and 
their caregivers.  The social-cognitive model (Corrigan, 2000; Corrigan & Watson, 2002) was 
used to understand how consumers’ and caregivers’ experiences in community pharmacy 
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translate into perception of self- and public stigma.  This model has previously been applied 
to understanding situational reactions to stigma (Corrigan & Watson, 2002).  In this model, 
markers or cues (such as atypical behaviour or a prescription for psychotropic medication) 
signal others about the presence of mental illness.  Such signals can lead to the perpetuation 
of stereotypes, for example “mentally ill people are dangerous”.  In turn, stereotypical 
thoughts may lead to negative behavioural reactions and discrimination (Corrigan, 2000).  
Individual and group interviews were undertaken in order to address the following research 
questions: 
 What are the perceptions or experiences of stigma, discrimination, and support in the 
community pharmacy setting from mental health consumers/caregivers’ perspectives? 
 What strategic improvements could be made to community pharmacy services to reduce 
the consumer/caregiver’s perceptions or experiences of stigma? 
 
Data and methods 
Participants 
The research was conducted in Australia (Queensland, New South Wales and Western 
Australia).  Participants were a convenience purposive sample of 74 consumers and 
caregivers.  Eight participants self-identified as Aboriginal or Torres Strait Islanders
1
.  Nine 
consumer/caregiver focus groups were conducted (n = 66 participants) with assistance from 
community mental health facilities.  The number of participants and the community facility 
for each focus group is summarised in Table 1.  According to personal preference or remote 
location, eight consumers/caregivers were interviewed individually rather than attend a focus 
group. 
                                               




INSERT TABLE 1 ABOUT HERE 
 
Materials 
A semistructured interview guide was developed for collecting data.  The content of the guide 
was informed by a similar instrument (University of South Australia, 2005) and a literature 
review investigating mental health consumers’ medication management needs (Mey et al., 
2013).  Following pilot interviews with two mental health consumers, the interview guide 
was amended to simplify language.  The topics explored in the interviews included 
experiences of community pharmacy, motivational issues, and cultural needs (Table 2).  The 
interview guide did not directly address stigma or discrimination. 
 
INSERT TABLE 2 ABOUT HERE 
 
Procedures 
Ethics approval was obtained from a University Human Research Ethics Committee.  
Participants provided their written consent.  Data were collected using semistructured 
individual and focus group interviews.  All interviews and focus group discussions were 
audio recorded.  Participants each received a $20 gift voucher as a token of appreciation.   
 
Individual interviews were conducted by a trained interviewer at a time and place that was 
convenient for the participants.  Five interviews were conducted by telephone, and three 
interviews took place face-to-face.  Each individual interview was approximately 30 minutes 
in duration (range 11 to 45 minutes).  Depending on the natural flow of dialogue, the number 
of trigger questions varied across interviews.  Prompts were used when necessary.  The 
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interviewer probed to explore additional ideas that arose during the interview, and exercised 
discretion in conducting each interview to ensure topics were covered sufficiently and that 
data saturation point was reached. 
 
Focus group interviews were held at community mental health facilities.  Two trained 
facilitators were present for each focus group.  One facilitator took field notes.  The other 
facilitator read and explained the consent material, and conducted the group interview.  An 
interpreter was available when required.  Focus group participants (n = 66) were given an 
optional one-page survey on their demographic characteristics, health conditions, and 
frequency of access to health care services.  Sixty-one completed survey forms were returned. 
 
Group interviews began with an introduction, explanation of purpose, and ground rules 
(“Please be respectful of other’s opinions”).  Participants were asked warm-up questions 
(“How often would you visit a community pharmacy?”).  The facilitator asked questions and 
used prompts as per the interview guide.  Two concluding questions elicited participants’ 
opinions on the most important focus group interview topic and additional thoughts or 
comments.  Group interviews took on average 1 hour to complete (range 40 minutes to 1 hour 
and 40 minutes).  Light refreshments were provided.  Facilitators met afterwards to debrief, 
compare notes and summarise topics. 
 
Analysis 
Interviews were transcribed verbatim and identifiable information was removed from the 
transcripts.  Analysis of the interview data followed the general inductive approach (Thomas, 
2006) and focused on themes emerging from participants’ responses describing perceptions 
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or experiences of stigma and discrimination in the community pharmacy context, elicited 




 software was used to manage the data.  Transcripts were read and re-read by two 
coders to gain an understanding of the broad issues and create ‘open codes’.  By discussion, 
the coders agreed on ‘axial codes’: a set of specific themes which captured core messages 
reported by the participants.  All transcripts were coded in this manner.  To ensure the 
process was reliable, two additional coders reviewed the codes and corresponding text units.  
This ensured that the framework of axial codes were sufficient to accurately capture the core 
messages and breadth and depth of participants’ experiences.  Finally, ‘selective codes’ were 
created that represented domains that emerged from the coded text, and key quotations that 
most strongly identified the selective codes were chosen.  The researchers maintained open 
dialogue throughout the analytical process.  This article focuses on the reporting of content 
relating to stigma that emerged through the data analysis process.  Other thematic elements to 
emerge will be reported elsewhere. 
 
Results 
The majority of the 74 participants were female (62%).  Other demographic characteristics 
are summarised in Table 3.  One participant reported an intellectual disability, one had 
cancer, and one had an acquired brain injury in conjunction with a mental health condition.  
Diagnostic information was not verified and is presented merely to help describe the sample. 
 
INSERT TABLE 3 ABOUT HERE 
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Three themes relating to stigma were identified: 1) perceived and experienced stigma can 
present a barrier to effective management of mental health, 2) self-stigma can impede 
consumers’ engagement with community pharmacy, and 3) positive relationships with 
community pharmacy staff reduce the experience of stigma.  Participants also provided 
potential solutions to reduce stigma in community pharmacy practice.  Themes are described 
using examples from the transcripts to illustrate.  As recommended by others (Sandelowski & 
Leeman, 2012), findings were translated into thematic statements by presenting quotes from 
transcripts along with statements representing thematic syntheses of the data.  Quotes have 
been identified with codes to indicate whether the participant was a consumer (C), caregiver 
(CR) or both (C/CR) and FG and SSI to indicate that the information was gathered in a focus 
group setting or semistructured interview, respectively.  
 
Stigma can Present a Barrier to Managing Mental Health 
Stigma was mentioned by most participants, and emerged as a major barrier to effective 
health management: 
 
The perception of stigma and discrimination . . . is personal.  It varies from person to 
person what that may be, but nevertheless . . . there is a tremendous underlying stigma 
and discrimination against mental ill health and people with mental ill health feel this 
(C/FG). 
 
Stigma was experienced in terms of self-stigma, and public stigma associated with 
interactions with pharmacy staff or the general public.  Participants referred to stigma directly 
through stories depicting their negative pharmacy experiences.  These experiences are 
reflected in the following statements:  
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There were a number of pharmacies I would go to where you tell that perhaps people 
went “Oh she’s on mental health drugs” because of the reaction . . . you could watch 
them putting stuff [medicines] together, and . . . The pharmacist looks.  You could see 
it across their face because it’s visible (C/CR/FG). 
 
I don’t like everyone knowing about my medication because I take lots of it and get 
accused that you’re on too much medicine all the time and I don’t like people 
knowing . . . my friends and that know, but not any other people.  I don’t like going 
into the chemist and they look at you because I go to pick up my Webster-pak
®
 [dose 
administration aid] and then I get extra medication that the doctor hasn’t put in and I 
do look like a big druggie walking out there, and I hate that, that thing that you see 
from other people (C/FG). 
 
Consumers and caregivers appeared to have a heightened awareness of judgemental or 
stigmatising attitudes and behaviours, were fearful of such experiences, and reported being 
subjected to such experiences by community pharmacy staff and other people in the 
pharmacy: 
 
Participant 1: . . . and the privacy and confidentiality because you’re not likely to open 
up about questions about antipsychotics or your drugs for schizophrenia or your 
bipolar medicine because there is a fear of being judged while you’re there . . .(C/FG). 
Participant 2: Also it’s quite likely that your neighbour or your workmate is in the 
chemist with you.  This is a small town (C/FG). 
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This young girl humiliated me in front of the whole chemist.  She said very loudly 
“Have you taken this before?” like she had a really dirty look on her face.  I said 
“Well I have been on it for a year now,” and then she turned around . . . behind the 
counter and she said “Oh she hasn’t had it in a year.”  She had obviously misheard 
me.  With that an older lady has come up and sort of tried to calm me down.  And I 
just said “I have been prescribed this drug by a psychiatrist.  I have taken it for a year.  
Here is my identification.  Can I please have my script?  I want to get the hell out of 
here now!”  I had never felt so bad in my life for being medicated! (C/FG). 
 
Linked to the need for non-stigmatising treatment was the need for consumers/caregivers to 
receive information in a way that respects their privacy and confidentiality, within an 
appropriate space and time:  
 
Why do I have to keep explaining myself to inexperienced staff?  I want to be treated 
with respect.  That’s all I ask for.  I mean it’s bad enough to have the illness.  It’s bad 
enough to have to go to the Doctor constantly to get scripts you know, I’ve got 
enough problems to deal with, than having to face that (C/FG). 
 
Perceptions such as these appeared to characterise the background against which some 
consumers might interpret their interactions with pharmacy staff.  Consumers called for 
increased awareness of privacy and confidentiality.  A private consultation room was 
perceived as desirable: 
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The pharmacy that I go to, there’s no real privacy area, you’re kind of still looking 
over the bench but everyone’s around with ears that go flap, flap, flap . . . particularly 
if you’re talking about mental health, there is stigma around it (C/FG). 
 
. . . they could just say, “Could you come with me please and we’ll discuss this” and 
go and address it in that little room with the door closed and no one else hears it and 
then you just walk back up the counter and pay . . . But that doesn’t happen.  What 
they do is they either come and they sit next to you where everyone can still hear you 
because it’s open, or they tell you at the front counter and it’s so embarrassing 
(C/FG). 
 
However, participants acknowledged the need for balance between pharmacies as a place of 
commerce versus pharmacy as a health care environment, and recognized that a private 
consultation space within the pharmacy is difficult to achieve.   
 
Self-Stigma can Impede Consumers’ Engagement with Community Pharmacy Services 
Although some participants reported that community pharmacy staff stereotyped and 
discriminated against them, they also acknowledged the potential influence of their own self-
perceptions.  The negative impact of self-stigma was seen as a barrier to medication 
adherence, accessing community pharmacy services, and other assistance-seeking 
behaviours: 
 
. . . [in the past] you never spoke about diagnosis but people had breakdowns and all 
the rest of it.  But that was [perceived as], “well that person obviously was a weak 
person because that happened to him.”  I was dealing with that when I was about 45 
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[years of age] and, as well as having a diagnosis, you actually go through that process 
[of thinking] “This is because I'm a weak person.” . . . We [consumers] feel because 
we've got this thing going wrong, that it's our fault, or we feel embarrassed about it.  
Some people feel that because they’ve been treated badly by some people, so you 
want to try sneak in [to the community pharmacy] and not make a fuss about it 
(C/SSI). 
 
There was also a theme of consumer acceptance of their health condition which tended to be 
associated with reduced self-stigma, for example: 
 
I’m just saying it’s not the pharmacy’s problem.  If we’ve [consumers] got problems 
with stereotypes and discriminations that’s our problem, not theirs (C/FG). 
 
I have come to the point where I am ok with my mental illness but there was a lot of 
shame around it for years but I am ok with it now (C/FG).  
 
The potential for interaction between self-stigma and public stigma to contribute to the 
perceptions of stigmatising attitudes from pharmacy staff also emerged, for example: 
 
. . . because of the stigma, if you’re working and have a good place in the community, 
you may not want people to know.  Even if you’re not working you may not want 
people to know (C/FG).  
 
Pharmacy processes such as long prescription waiting times, saying medication names, or 
avoidant behaviour by the pharmacist (who serves as a role-model for other staff) were seen 
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to perpetuate the consumers’ experience of stigma.  For example, one consumer reported that 
having to wait for her prescription to be filled within the pharmacy can make her agitated and 
could trigger a panic attack.  Her perception was that the pharmacy staff would not 
understand this, mistake her behaviour for intoxication, and respond negatively:  
 
. . . because I get shakes really bad too, so I get real worried about going out in public.  
So pretty much I hope that they don't think that I'm drunk or that I'm - the way they 
look down on you, or something, like there's something wrong with you. . . Because I 
have anxiety, I just want to get in there and get out as fast as possible.  But sometimes 
the wait just like really gets to [me] and [I’m] just sitting there for ages.  Sometimes 
they just take forever, and that's probably the worst thing, that’s what happens to me 
[when] waiting for so long (C/SSI). 
 
Interviews also revealed that types of medications prescribed, and the packaging that 
medications come in can act as illness markers, which consumers perceive as triggers for 
negative attitudes from others.  
 
Good Relationships with Staff Reduce the Experience of Stigma 
Participants described how positive relationships with knowledgeable and understanding 
pharmacy staff members reduced their perception of the stigma of mental illness.  Improved 
general knowledge about mental disorders was seen as a fundamental way to promote such 
effective consumer-staff relationships:  
 
A more general knowledge, a wider knowledge of the specific drugs, what they do, 
how they can help people, and that they don’t all suit each personality (because we’re 
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all different), but not to add stigma to the people because there’s enough stigma on 
people with mental health issues.  And when you’re depressed and then you get added 
pressure from people who are serving you, it makes you feel worse (C/CR/FG). 
 
When consumers saw pharmacists as approachable and easy to talk to, this was associated 
with absence of stigma or feeling labelled.  Consumers described how they felt at ease to 
speak openly with approachable pharmacists: 
 
He’s a very approachable [pharmacist].  He is genuine.  He doesn’t project any feeling 
of fear to the client or distrust.  I would say that in old medical terminology, he’s got 
good bedside manner (C/CR/FG).  
 
Solutions to Reduce Stigma in the Community Pharmacy Setting 
Several solutions to reduce stigma were offered by participants.  These include education to 
increase staff awareness of stigma, improve communication with mental health consumers 
and caregivers, and increase knowledge of pharmacotherapy, mental health management and 
strategies to promote recovery:  
 
There needs to be more education about that and how to explain that in the manner to 
the client that is not demeaning, that is enabling and giving people their respect back 
regardless of how they’re feeling.  Because when you’re depressed, and already 
feeling like a worm, you don’t need to feel like “Oh, I need this tablet or these tablets 
for my, these antidepressants,” and to go and be made to feel you’re going through the 
mill because you need those tablets (C/CR/FG). 
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Participants commented on the need to address stigma with all staff members whom interact 
with customers, and that stigma awareness should be included in support staff training.  This 
could be achieved by nurturing a culture of valuing the customer, and developing more 
effective communications between pharmacy staff and customer: 
 
I don’t know whether they [community pharmacy staff] currently get training in 
dealing with people who may be confused just because any illness can make you 
confused, but people with dementia, people who maybe psychotic or even just 
understanding that if you’re feeling really depressed what an effort it is to get to there.  
So I don’t know whether they get training in that, but that would be really helpful; just 
understanding a little bit of what it’s like to experience mental illness (C/FG). 
 
Practical suggestions that could be implemented to reduce stigma in pharmacy practice were 
given:  
 
From my experience of turning up at pharmacies, there is a variety of reactions from 
staff, stigmatised reactions . . . The [pharmacy] experience can be good just from 
explanations about things quietly, off to the side rather than across the counter in front 
of people, or calling out people's names in front of people, where the medication is 
visible.  Because these sorts of things . . . feed into the stigma if people recognise 
what the box is, or recognise the person's name, or overhear the conversations about 
the particular issues around the drugs, that [community pharmacy staff] need to be 
aware of.  Just minor things that can be done differently that would make the 
experience easier for the consumer (CR/SSI). 
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From a caregiver’s viewpoint, the above passage summarised the typical consumers’ 
perceptions, experiences, and strategies. 
 
Discussion 
In this exploratory study, three themes relating to stigma emerged, and simple practical 
strategies were suggested.  Findings are discussed in relation to each theme, then potential 
recommendations are given, and limitations are discussed.  
 
Perceived and experienced stigma can present a barrier to effective management of mental 
health.  As previously documented in the context of the public, health professionals, and 
students (Bell et al., 2010; Jorm et al., 1999; Mental Health Council of Australia, 2011; 
Volmer et al., 2008), stigma from staff was perceived in the Australian community pharmacy 
setting despite the mental health education pharmacists receive during their training.  
Consistent with the social-cognitive model (Corrigan, 2000; Corrigan & Watson, 2002), 
public stigma in the community pharmacy setting was perceived in subtle cues including ‘a 
look’, a facial expression, or a ‘sense’ from other people.  Similar consequences of perceived 
stigma have been reported in the context of help seeking from a GP, psychiatrist, mental 
health service (Mental Health Council of Australia, 2011).  This qualitative research adds 
knowledge of mental health consumers’ personal experiences and perceptions of stigma in 
the context of community pharmacy.  
 
Self-stigma can impede consumers’ engagement with community pharmacy.  The experience 
of self-stigma related to negative self-beliefs (Corrigan & Watson, 2002), and in this study, 
existed on a spectrum ranging from embarrassment to shame.  Current findings build on 
previous work (Black et al., 2009) for example, it is known that people who perceive self-
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stigma might postpone help-seeking (Wrigley, Jackson, Judd, & Komiti, 2005) or avoid 
hospitalisation (Link & Cullen, 1986; Link, Cullen, Frank, & Wozniak, 1987; Link, Phelan, 
Bresnahan, Stueve, & Pescosolido, 1999).  Transcripts exemplified that the consumers’ 
perception of stigma can negatively impact their willingness to visit a community pharmacy, 
obtain prescription medications, or to engage with pharmacy staff; all of which can affect 
treatment outcomes (Sirey et al., 2001).  To the extent that staff are not aware of the 
consequences and the impact on consumers’ behaviour, or lack skills to manage it, they might 
unintentionally contribute to the consumers’ experience or perception of st igma. 
 
Current results further characterise the phenomenon of self-stigma.  For example, persons 
with mental illness previously reported being aware of negative stereotypes about them 
(Corrigan & Watson, 2002), but did not necessarily subscribe to such beliefs (Hayward & 
Bright, 1997).  Consumers’ response to stigma depends on the situation (Corrigan & Watson, 
2002) and other factors including recovery expectations (Muñoz, Sanz, Pérez-Santos, & 
Quiroga, 2011) or sense of meaning in life (Ehrlich-Ben Or et al., 2013).  When others’ 
negative responses are viewed as unjust or irrelevant by the consumer, there might be little 
reduction in self-esteem due to stigma (Corrigan & Watson, 2002).  Accordingly, some 
participants in this study responded to stigma with indifference.   
 
As described in the social-cognitive model (Corrigan & Watson, 2002), consumers perceived 
that signals such as their behaviours or symptoms might trigger stereotypes among 
community pharmacy staff, which might mediate stigmatising staff behaviour.  Consistent 
with previous findings(Boyd Ritsher, 2003), participants in this study avoided contact with 
community pharmacy staff or other mental health service providers, and described using 
selective disclosure (Wahl, 1999) of personal information within the pharmacy setting as a 
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strategy to avoid negative reactions or experiences.  This consumer behaviour can severely 
restrict their interactions with pharmacy staff, limit opportunities for provision of care, and 
have an impact on consumer health outcomes. 
 
Positive relationships with community pharmacy staff reduce the experience of stigma.  As 
previously demonstrated (Black et al., 2009; Mental Health Council of Australia, 2011), 
stigma was identified as a barrier to effective management of mental health because 
consumers associated stigma with fear and distrust.  As per previous findings (Wahl, 1999), 
consumers reported coping with stigma through exercising choice: in selective disclosure to 
others, and in their selection of pharmacy.  The overall impact of stigma was to prevent 
formation of trusting therapeutic relationships in community pharmacy, which are known to 
be crucial in the provision of health care and particularly for medication adherence (for 
example, Jon & Wiederholt, 1995; Penn, Watermeyer, & Evans, 2011). 
 
Traditionally, pharmacy students’ education on mental health emphasised pharmacology and 
medicines over communication skills (Pharmaceutical Society of Australia, 2013).  Emerging 
research shows that current curricula regarding mental health for pharmacists in Australian 
accredited courses is predominantly biomedically oriented, and psychosocial aspects 
including the consumer’s experience of stigma appear to be lacking (A. Mey, personal 
communication, January 16, 2013).  In addition, about three-quarters of community 
pharmacy patrons will interact with a support staff member rather than a trained pharmacist 
during their pharmacy visit (University of South Australia, 2005).  Given that there appears to 
be a positive association between familiarity with mental illness and acceptance of people 
with mental health issues (Angermeyer & Dietrich, 2006), current findings suggest that 
knowledge of consumer’s experience of mental illness, education content delivered by 
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consumers themselves, along with training in communication skills for pharmacy staff, seem 
warranted.  Consumers in this study offered simple, practical suggestions such as increased 
general knowledge of mental illness and cultural sensitivity as central to the process of being 
welcoming and building a therapeutic relationship.   
 
Lack of privacy appeared to impede the formation of relationships, which can augment 
perceived stigma within community pharmacy.  Mental health care consumers and caregivers 
recognized community pharmacy’s dual role as a place of commerce and a health care 
environment, and acknowledged that a private space is difficult to achieve.  These findings 
highlight the importance of creating the conditions for open communication between 
community pharmacy staff and consumers to promote positive mental health experiences.  
This might necessitate a broader conceptualisation of pharmacy space to include personalised 
follow-up by phone, email or other means, once the consumer is away from the physical 
pharmacy environment (Rapport, Doel, & Jerzembek, 2009; Wheeler, Barrows, & Burgess, 
2012).  
 
Recommendations.  Pharmacy staff might benefit from understanding how customer groups’ 
needs differ (not only mental health consumers), and adopt a holistic, patient-centred care 
approach.  Consumers and caregivers suggested strategies which indicated an opportunity to 
introduce mental health training for community pharmacy staff to increase their awareness of 
stigma, improve communication skills, and reduce the negative experience of stigma with the 
Australian community pharmacy context.  Ideally, such training would acknowledge the 
nuanced ways in which public stigma and self-stigma are manifest, reducing the opprobrium 
of mental illness and fostering positive relationships.  Attention should be given to the 
consumers’ personal response to stigma in Australian pharmacy curricula at undergraduate 
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and postgraduate levels, and in continuing professional development for pharmacists.  These 
interventions are likely to benefit other pharmacy customers, not only those with a mental 
illness.   
 
Strategies that foster open communication at the appropriate time and space within the 
community pharmacy environment should be adopted.  Notably, a culture of welcoming and 
valuing customers would ideally extend to any community pharmacy staff whom come into 
contact with customers, including students and support staff.  Practical suggestions also 
included creating suitable consultation areas within the pharmacy, and reduced consumer 
waiting times through development of more streamlined practices, and might involve 
enabling consumers/caregivers to phone ahead or arrange a designated time to collect 
prescription medicines.  These interventions would require careful reconsideration of 
pharmacy layout and workflow, but could result in more effective care, higher 
customer/consumer retention, and increased consumer satisfaction.  Further research would 
be required to evaluate such practical applications. 
 
Limitations.  Purposive sampling potentially introduced recruitment bias towards motivated 
participants.  However, purposive sampling was the most appropriate method of ensuring that 
the perspectives of consumers and caregivers were included (Buetow, 2007).  Participants in 
this study represented a wide range of mental illness groups.  In this study, mental illness was 
defined broadly.  As such, recommendations might not apply to specific diagnoses, and are 
intended as general suggestions only.  Further work on consumer perspectives should 
endeavour to include other underrepresented groups including Aboriginal and Torres Strait 
Islander people, the homeless, less educated persons, and culturally or linguistically diverse 
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populations.  Future studies should compare results over time to evaluate the efficacy of 
training and education for all community pharmacy staff. 
 
Conclusion 
The stigma of mental illness is a commonly encountered phenomenon in many health care 
settings worldwide.  In-depth qualitative consultation revealed that mental health consumers 
and caregivers perceived stigma and discrimination in the Australian community pharmacy 
setting.  Attempts to better manage mental illness and reduce stigma seem justified, and 
suggestions for how this can be achieved were apparent.  Along with strategic practical 
suggestions, three main themes emerged: 1) stigma is a barrier to effective management of 
mental health, 2) self-stigma can impede consumer engagement with community pharmacy 
services, and 3) positive relationships with knowledgeable staff are important in reducing 
stigma.  The current findings improve our understanding of the management of mental health 
in the Australian setting, and promote the importance of pharmacy as a safe health care space.  
As part of a larger project, findings from this study will inform training and professional 
development interventions for pharmacy staff.  Interventions might include education to 
increase awareness of the consumers’ and caregivers’ personal responses to mental illness 
stigma, introduction of strategic and targeted practice improvements, and enabling 
community pharmacy staff to better support consumers’ mental health.  In pharmacy practice, 
stigma perceived by consumers and caregivers is likely to adversely affect the provision of 
care to consumers (Healthcare Management Advisors, 2010; Jorm et al., 1999; Nordt et al., 
2006; Scheerder et al., 2011).  As shown in this study, stigma can also adversely affect 
consumer’s choice of pharmacy, adherence and ultimately their health management.   
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Community mental health facility Length  
Consumers Caregivers   
9 0 Not for profit support organisation for those living in 
shared or supported social housing 
0:56:00 
11 0 Community-based not for profit support organisation 0:40:30 
2 1 Regional community mental health service 1:14:00 
10  Not for profit organisation run by mental health 
consumers 
1:16:00 
5 1 Remote regional community mental health service 1:30:00 
10  0 Non-government multicultural mental health centre 
(non-English speaking participants) 
0:53:30 
3 0 Peak body consumer support organisation 0:47:00 
8 1 Consumer-run community support organisation 0:33:45 
0 5 Caregiver support network 0:47:00 
2 
Table 2.  Interview framework 
 
Current level of knowledge of community pharmacy 
Expertise and Role of the pharmacist 
Role of the support staff 
Services provided / available 
Current needs from community pharmacy 
Health care, treatment, product needs 
Information, advice, reassurance 
Deficiencies in service currently provided 
Who is responsible for changes 
Past and present experiences of community pharmacy 
Current use of community pharmacy in management of mental illness 
Strengths of current experience 
Who is responsible for changes 
Current expectations of community pharmacy 
How well are expectations currently being met 
How can shortfalls be addressed 
Engagement in changes 
Perceptions of medicine taking 
Role of community pharmacy / consumer 
Barriers to adherence /motivation 
Efficacy of treatment management Potential future role for pharmacy 
Cultural needs/beliefs/issues 
3 
Table 3.  Participant Demographic Characteristics 
Age in 
years 
n (%) Frequency of 
pharmacy visit 
n (%) Frequency of health 
professional visit 
n (%) Self-reported mental health 
conditions 
n (%) 
18-25 3 (4.0) Monthly 20 (27.3) Monthly 26 (35.1) Depression 23 (31.1) 
26-40 13 (17.6) Fortnightly 16 (21.6) Fortnightly 16 (21.6) Anxiety disorder 18 (24.3) 
41-55 23 (31.1) Weekly 15 (20.3) Weekly 0 (0.0) Bipolar affective disorder 11 (14.9) 
> 55 22 (29.7) Other 9 (12.1) Other 17 (22.9) Schizophrenia or psychotic 
disorder 
13 (17.6) 
Missing 13 (17.6) Missing 14 (18.9) Missing 15 (20.3) Missing 9 (12.1) 
Total 74  74  74  74 
Note:  Semi-structured interview participants were not asked demographic questions, and some focus group participants chose not to provide 
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